Elanco Animal Health (NYSE:ELAN – Free Report) had its target price trimmed by Barclays from $20.00 to $19.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently ...

Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Elanco has struck an agreement to distribute a vaccine that may protect cattle for up to 12 months against bird flu ...

Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...

Elanco Animal Health Inc (ELAN) reports robust organic growth and significant debt reduction, setting a positive outlook for ...

Zoetis also has an H5N1 vaccine, for which it received a conditional license in 2016 and a contract award for the USDA’s ...

Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.

Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.

Elanco Animal Health (NYSE:ELAN) stock falls as the company reports mixed Q4 2024 results, and sets 2025 outlook below consensus due to forex headwinds. Read more here.